Physician initiated, prospective, non-randomized Multicenter trial, investigating the safety and Efficacy of the tReatment with Luminor DCB and Angiolite BTK DES in TASC C and D tibial Occlusive disease iN patients with critical limb ischaemia at 12-month follow up.
DESCRIPTION
Device
Luminor 14m & Angiolite BTK as bailout stenting
Number of patients
50
Follow up
2 years
Type of lesions
Long tibial occlusive lesions TASC C&D
OUTCOMES
MERLION 1 year outcomes 1
fTLR
AFS
PP
1- T. Tang et al. Physician initiated, prospective, non-randomized Multi-center trial, Investigating the safety and Efficacy of the TReatment with the Luminor Drug Coated Balloon and the Angiolite Drug Eluting Stent of IVascular in TASC C and D Tibial Occlusive disease iN patients with critical limb ischemia– 12-month results. International Angiology, May 2021.
CONCLUSIONS
“Luminor DCB is safe and efficious in BTK lesions”
Luminor DCB is safe and efficacious, in treating highly complex infra-popliteal atherosclerotic lesions in challenging CLTI patients. Luminor is associated with highly satisfactory acute technical success, 6-month target lesion patency and AFS.
MERLION Trial
MAIN INVESTIGATOR
Dr T. Tang
General Hospital (Singapore)
